Pfizer Considers Selling Its Businesses - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pfizer Considers Selling Its Businesses


ePT--the Electronic Newsletter of Pharmaceutical Technology

Pfizer is considering divesting some of its businesses to maximize their value, according to remarks made by Mikael Dolsten, Pfizer’s president of worldwide research and development, at a Barclays Capital investor conference last Thursday. “We are going through a comprehensive review that we aim to complete during this year,” said Dolsten.

Pfizer CEO Ian Read has remarked that the company’s core and adjacent businesses are successful, said Dolsten at the conference. “But we need also to understand what is the maximum value for those businesses, which of them actually have a higher value by being inside Pfizer and can benefit from the capabilities and our financial strengths, our reach in the market, and which would do better as businesses and create more value for shareholders to be outside the company,” said Dolsten.

Dolsten’s remarks confirmed a Mar. 14, 2010, research report by Tim Anderson, an analyst with investment firm Sanford Bernstein. Pfizer might spin off or sell its nonpharmaceutical divisions, including nutritionals and animal health, as well as its established-products unit that focuses on off-patent medicines, according to the report. Divestments could reduce Pfizer’s revenue base to $35–40 billion from $67 billion, said the report, as reported in Bloomberg Businessweek.

Divesting certain businesses could boost Pfizer’s stock price, and investors and analysts are debating whether Read should pursue this strategy. A series of mergers, including the high-profile acquisition of Wyeth, have made Pfizer a bloated organization, according to critics. On Mar. 1, 2011 King Pharmaceuticals became a wholly owned Pfizer subsidiary, thus signaling the completion of the latter company’s latest acquisition.

See related Pharm Tech articles:

Pfizer Site Closure “Shocking Wake-Up Call” for UK (blog post)

Pfizer to Purchase King Pharmaceuticals (ePT)

Pfizer’s Maddaluna on Integrating Wyeth’s Manufacturing Organization (podcast)

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here